EGFR and non-small cell lung carcinoma: The results from the LUX-Lung 2/3/6 trials (9, 20, 21) indicate that afatinib can be used as first-line treatment of metastatic NSCLC with non-resistant EGFR mutation including L861Q/G719X/S768I.